13 completed. 13 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 13 |
Follow Clostridium Difficile Infection: new trials by email Literature Review of Clostridium Difficile Infection trials Research Report on Clostridium Difficile Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection Vancomycin, Placebos - Clostridium Difficile Infection | Phase 3 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 263 | 2020-11-19 | 2025-12-10 |
| Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) RBX2660 - Clostridium Difficile Infection, Infection | Phase 3 | Completed | Rebiotix Inc. | 793 | 2019-07-30 | 2024-08-07 |
| Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001) Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD) - Clostridium Difficile Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 148 | 2018-03-27 | 2023-07-27 |
| ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection SER-109, Placebo - Clostridium Difficile Infection | Phase 3 | Completed | Seres Therapeutics, Inc. | 182 | 2017-07-10 | 2023-04-27 |
| Clostridium Difficile Vaccine Efficacy Trial Clostridium difficile vaccine, Placebo - Clostridium Difficile Infection | Phase 3 | Completed | Pfizer | 17535 | 2017-03-29 | 2023-02-13 |
| Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection Fecal microbiota transplantation, Fidaxomicin, Vancomycin - Clostridium Difficile Infection | Phase 3 | Completed | University of Aarhus | 64 | 2016-04-01 | 2019-10-15 |
| Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea Cadazolid, Vancomycin, Cadazolid-matching placebo - Clostridium Difficile Infection | Phase 3 | Completed | Actelion | 632 | 2014-03-27 | 2025-02-04 |
| Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea Cadazolid, Vancomycin, Cadazolid-matching placebo - Clostridium Difficile Infection | Phase 3 | Completed | Actelion | 631 | 2013-12-12 | 2025-02-04 |
| Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) Surotomycin, Vancomycin, Placebo - Clostridium Difficile Infection | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 606 | 2012-05-16 | 2019-07-23 |
| A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006) CB-183,315, Vancomycin, Placebo - Clostridium Difficile Infection | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 608 | 2012-05-16 | 2022-08-22 |
| A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002) MK-6072, MK-3415A, Placebo - Clostridium Difficile Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1203 | 2012-02-01 | 2018-09-05 |
| A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) MK-3415, MK-6072, MK-3415A - Clostridium Difficile Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1452 | 2011-10-10 | 2018-09-05 |
| Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children L reuteri in children on antibiotics - Antibiotic Associated Diarrhea, Clostridium Difficile Infection | Phase 3 | Completed | St Marina University Hospital, Varna, Bulgaria | 100 | 2011-02-01 | 2013-09-10 |
Clostridium Infections (13) · Diarrhea (4) · Communicable Diseases (1) · Enterocolitis, Pseudomembranous (1) · Gastroenteritis (1) · Infections (1)
Bacterial Infections (13) · Bacterial Infections and Mycoses (13) · Gram-Positive Bacterial Infections (13) · Infections (12) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Signs and Symptoms, Digestive (4) · Digestive System Diseases (2) · Gastrointestinal Diseases (2) · Disease Attributes (1) · Enterocolitis (1) · Gastroenteritis (1) · Intestinal Diseases (1) · Pathologic Processes (1)
Vancomycin (6) · bezlotoxumab (3) · CB-183,315 (2) · cadazolid (2) · Fecal Microbiota Transplantation (1) · Fidaxomicin (1) · actoxumab (1)
Merck Sharp & Dohme LLC (3) · Actelion (2) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Pfizer (1) · Rebiotix Inc. (1) · Seres Therapeutics, Inc. (1) · St Marina University Hospital, Varna, Bulgaria (1) · University of Aarhus (1)
Canada (4) · United States (4) · Argentina (2) · Bulgaria (2) · Colombia (2) · Czechia (2) · Germany (2) · Hungary (2) · Poland (2) · Portugal (2) · Spain (2) · Sweden (2) · United Kingdom (2) · Australia (1) · Belgium (1)
Anne Claire Marrast, MD (2) · Emily G McDonald, MD MSc (1) · Jens F Dahlerup, MD DrMSc (1) · Lisa von Moltke, MD (1) · Miglena I Georgieva, PhD (1) · Teena Chopra, M.D., M.P.H. (1) · Todd C Lee, MD, MPH (1)
PMID 28121498, PMID 29538686, PMID 29680101, PMID 29788418, PMID 30060024, PMID 30227108, PMID 30455246, PMID 30460321, PMID 30709665, PMID 31411386, PMID 31628838, PMID 32099847, PMID 32376702, PMID 32504314, PMID 32747931, PMID 36661328, PMID 27316794, PMID 28480267, PMID 28961905, PMID 30610862, PMID 31846705, PMID 31883370, PMID 32101275, PMID 35045228, PMID 35463939, PMID 36716031, PMID 36906440, PMID 37389891, PMID 38941068, PMID 39180325, PMID 39180326, PMID 40177588, PMID 40784972, PMID 41245385, PMID 41491103, PMID 41653256, PMID 41758514, PMID 42286373, PMID 42840322
2016 (1), 2017 (1)